Moderna's experimental COVID-19 vaccine shows promise in early-stage study

Moderna Inc said on Monday its experimental vaccine for COVID-19 showed promise in early trials and it looks to advance the vaccine into late-stage trials in July.

The vaccine, mRNA-1273, was also found to be generally safe and well-tolerated in the early-stage study, the drug developer said.